Lung cancer trial of RET inhibitor selpercatinib achieves durable responses in majority of patients with RET gene fusions
For patients with non-small cell lung cancers (NSCLC) marked by RET gene fusions, the targeted…
Browsing: Selpercatinib
FDA approves selpercatinib for lung and thyroid cancers with RET gene mutations or fusions
The Food and Drug Administration (FDA) granted accelerated approval to selpercatinib for the following indications:…
Updated results on genomically tailored therapy for lung cancer patients
Selpercatinib was granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration in 2018…